Education
About Us
Working with TipRanks
Follow Us
Lonza Group Ltd (SG:O6Z)
SGX:O6Z
O6Z Analyst Ratings
Strong Buy
3 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
O6Z Stock 12 Month Forecast
Average Price Target
S$1,101.11
▲(1311.86% Upside)
| Highest Price TargetS$1,218 | Average Price TargetS$1,101 | Lowest Price TargetS$1,019 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
S$980.2
Buy
1156.83%
Upside
Reiterated
11/01/25
AI Generated ArticleAI Generated Article
Barclays
S$1,083.72
Buy
1289.57%
Upside
Reiterated
10/27/25
Kepler Capital
S$1,083.72
Buy
1289.57%
Upside
Reiterated
10/23/25
Deutsche Bank
S$1,217.98
Buy
1461.71%
Upside
Reiterated
09/26/25
RBC Capital
S$1,019.02
Hold
1206.61%
Upside
Reiterated
09/11/25
UBS
S$1,051.37
Buy
1248.09%
Upside
Reiterated
07/28/25
J.P. Morgan
S$1,051.37→S$1,091.81
Buy
1299.94%
Upside
Reiterated
07/28/25
Berenberg Bank
S$1,099.9
Buy
1310.31%
Upside
Reiterated
07/25/25
Exane BNP Paribas
S$1,140.34
Buy
1362.16%
Upside
Initiated
05/29/25
DBS
S$960.64→S$1,065.71
Buy
1266.46%
Upside
Reiterated
02/14/25
Lonza Group Ltd: Strategic Expansion and Geopolitical Opportunities Drive Buy RatingWe have a BUY rating on Lonza, with a TP of CHF710. We have a BUY rating on Lonza, with a TP of CHF710. of innovative biologics technologies to bring in new customers with high stickiness. Provider of innovative biologics technologies to bring in new customers with high stickiness. Lonza’s earnings outlook is positive, with its consensus having forecasted an EPS CAGR of 15.5% between 2024- 27F – higher than its historical EPS CAGR of 5.9% during 2021-24. The positive outlook is likely due to 1) an increased company focus on new tech such as antibody-drug conjugates (ADCs) and cell & gene, making them top picks for cooperation with innovative drug makers (cell & gene revenue contribution: 7% in 2019 vs 10% in 2024); 2) a long history combined with customer stickiness, which leads to large recurring revenues.
Morgan Stanley
S$970.5→S$1,010.94
Hold
1196.24%
Upside
Downgraded
02/12/25
KeyBanc
S$986.67→S$1,027.11
Buy
1216.98%
Upside
Reiterated
01/30/25
Jefferies
S$1,172.69→S$1,179.16
Buy
1411.93%
Upside
Reiterated
01/30/25
CFRA
S$986.67→S$1,067.55
Buy
1268.83%
Upside
Reiterated
01/29/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
S$980.2
Buy
1156.83%
Upside
Reiterated
11/01/25
AI Generated ArticleAI Generated Article
Barclays
S$1,083.72
Buy
1289.57%
Upside
Reiterated
10/27/25
Kepler Capital
S$1,083.72
Buy
1289.57%
Upside
Reiterated
10/23/25
Deutsche Bank
S$1,217.98
Buy
1461.71%
Upside
Reiterated
09/26/25
RBC Capital
S$1,019.02
Hold
1206.61%
Upside
Reiterated
09/11/25
UBS
S$1,051.37
Buy
1248.09%
Upside
Reiterated
07/28/25
J.P. Morgan
S$1,051.37→S$1,091.81
Buy
1299.94%
Upside
Reiterated
07/28/25
Berenberg Bank
S$1,099.9
Buy
1310.31%
Upside
Reiterated
07/25/25
Exane BNP Paribas
S$1,140.34
Buy
1362.16%
Upside
Initiated
05/29/25
DBS
S$960.64→S$1,065.71
Buy
1266.46%
Upside
Reiterated
02/14/25
Lonza Group Ltd: Strategic Expansion and Geopolitical Opportunities Drive Buy RatingWe have a BUY rating on Lonza, with a TP of CHF710. We have a BUY rating on Lonza, with a TP of CHF710. of innovative biologics technologies to bring in new customers with high stickiness. Provider of innovative biologics technologies to bring in new customers with high stickiness. Lonza’s earnings outlook is positive, with its consensus having forecasted an EPS CAGR of 15.5% between 2024- 27F – higher than its historical EPS CAGR of 5.9% during 2021-24. The positive outlook is likely due to 1) an increased company focus on new tech such as antibody-drug conjugates (ADCs) and cell & gene, making them top picks for cooperation with innovative drug makers (cell & gene revenue contribution: 7% in 2019 vs 10% in 2024); 2) a long history combined with customer stickiness, which leads to large recurring revenues.
Morgan Stanley
S$970.5→S$1,010.94
Hold
1196.24%
Upside
Downgraded
02/12/25
KeyBanc
S$986.67→S$1,027.11
Buy
1216.98%
Upside
Reiterated
01/30/25
Jefferies
S$1,172.69→S$1,179.16
Buy
1411.93%
Upside
Reiterated
01/30/25
CFRA
S$986.67→S$1,067.55
Buy
1268.83%
Upside
Reiterated
01/29/25
Best Analysts Covering Lonza Group Ltd
1 Month
xxx
Success Rate
6/8 ratings generated profit
Average Return
+4.29%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +4.29% per trade.
3 Months
xxx
Success Rate
6/8 ratings generated profit
Average Return
+2.35%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +2.35% per trade.
1 Year
Success Rate
8/8 ratings generated profit
Average Return
+9.46%
reiterated a buy rating 10 months ago
Copying James Vane's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +9.46% per trade.
2 Years
xxx
Success Rate
7/8 ratings generated profit
Average Return
+9.88%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +9.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
O6Z Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
0
0
0
0
0
Buy
10
15
12
12
8
Hold
7
13
10
9
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
28
22
21
12
Each month's total comprises the sum of three months' worth of ratings.
O6Z Financial Forecast
O6Z Stock Forecast FAQ
What is SG:O6Z’s average 12-month price target, according to analysts?
Based on analyst ratings, Lonza Group Ltd’s 12-month average price target is 1,101.11.
What is SG:O6Z’s upside potential, based on the analysts’ average price target?
Lonza Group Ltd has 1311.86% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Lonza Group Ltd a Buy, Sell or Hold?
Lonza Group Ltd has a consensus rating of Strong Buy, which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.
What is Lonza Group Ltd’s share price target?
The average share price target for Lonza Group Ltd is 1,101.11. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is S$1,217.98 ,and the lowest forecast is S$1,019.02. The average share price target represents 1311.86% Increase from the current price of S$77.99.
The highest analyst share price target is S$1,217.98 ,and the lowest forecast is S$1,019.02. The average share price target represents 1311.86% Increase from the current price of S$77.99.
What do analysts say about Lonza Group Ltd?
Lonza Group Ltd’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of Lonza Group Ltd?
To buy shares of SG:O6Z, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.